A Randomised, Double-blind, Parallel Group, Placebo Controlled, 4-Week, Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults with Asthma - Artemisia study

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510291-32-00

Acronym

D8210C00005

Enrollment

Registered

2024-09-02

Start date

2024-09-26

Completion date

2025-08-13

Last updated

2025-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Brief summary

Change from baseline to end of IMP administration in expression of T2, non-T2, and JAK1-related genes and gene signatures in bronchial brushings.

Detailed description

Change from baseline to end of IMP administration in STAT phosphorylation in bronchial biopsies, Change in number of airway cells, including but not limited to inflammatory cells, airway smooth muscle cells, and goblet cells from baseline to end of IMP administration in bronchial biopsies (cells per mm² determined by microscopic evaluation)

Interventions

DRUGAZD4604

DRUGAzd4604 placebo

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Change from baseline to end of IMP administration in expression of T2, non-T2, and JAK1-related genes and gene signatures in bronchial brushings.	—

Secondary

Measure	Time frame
Change from baseline to end of IMP administration in STAT phosphorylation in bronchial biopsies, Change in number of airway cells, including but not limited to inflammatory cells, airway smooth muscle cells, and goblet cells from baseline to end of IMP administration in bronchial biopsies (cells per mm² determined by microscopic evaluation)	—

Countries

Denmark, Germany, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026